The medtech giant designed Navitor as the only self-expanding TAVI system with leaflets within the native valve. This design helps improve access to coronary arteries to facilitate future procedures that treat coronary artery disease.
Navitor currently has U.S. approval to treat symptomatic severe aortic stenosis in those at high or extreme risk for open-heart surgery. This includes patients with considerations related to age, frailty, or other health conditions. Abbott said its TAVI system represents a viable and less invasive option for this patient population.
Abbott launched the latest generation of the valve in 2024, then won expanded CE mark approval in August 2025.
Sandra Lesenfants, SVP of Abbott’s Structural Heart business, shared findings on LinkedIn after a presentation at EuroPCR 2026 in Paris.
According to Lesenfants, Navitor demonstrated favorable safety and performance outcomes in low- and intermediate-risk patients. Findings included 1.9% all-cause mortality or disabling stroke, 1.2% stroke, 0% coronary obstruction and 100% coronary access when needed.
Lesenfants wrote in her LinkedIn post:
“These results reinforce the strong safety, sustained hemodynamics, and durability of the Navitor Valve — and highlight Navitor’s future-ready design. At Abbott, we are focused on advancing innovation, expanding access to meaningful data, and keeping patients at the center of every conversation and every breakthrough.”
